The molecular basis for inhibition of adipose conversion of murine 3T3-L1 cells by retinoic acid.
The effect of retinoic acid (RA) on the adipose conversion of 3T3 cells has been studied. Differentiation of 3T3-L1 cells was initiated by addition of 0.5 mM methylisobutylxanthine, 0.3 microM dexamethasone and 10 micrograms/ml insulin (MDI) to confluent monolayers of preadipocytes for 48 h. During this time, the cells underwent DNA replication and cell division prior to the expression of adipose specific genes. RA administration had no apparent effect on the rate or extent of cell growth, cell division, or DNA replication. However, RA treatment concomitant with MDI addition inhibited triacylglycerol accumulation (I0.5 = 6 nM) and the accumulation of the differentiation-dependent mRNAs encoding the adipocyte lipid-binding protein (ALBP) and stearoyl-CoA desaturase 1 (SCD1). No inhibition occurred with RA addition either prior to or after MDI treatment. Runoff transcription revealed that the inhibitory effects of RA occurred at the level of transcription and were persistent. Cells treated with RA during the MDI regimen did not appreciably transcribe ALBP or SCD1 mRNAs several days following RA withdrawal. The effects of RA were specific for differentiation-dependent transcripts: 10(-6) M RA did not inhibit expression of the mRNAs encoding beta-tubulin or glutamine synthase. Examination of immediate-early transcription factor expression during the MDI regimen revealed that RA mediated an elevated, prolonged expression of c-Jun mRNA accompanied by diminished expression of c-Fos and Jun-B mRNAs. Given the previously demonstrated role of transcription factor AP-1 in ALBP gene expression, our results suggest that the initiation of expression of this and other adipocyte-specific genes during adipose conversion is regulated by the relative composition of transcription factor AP-1.
Stone
R L
RL
Department of Biochemistry, University of Minnesota, Saint Paul 55108.
Bernlohr
D A
DA
D000273:Adipose Tissue / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division; D002460:Cell Line; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D015870:Gene Expression / Q000187:drug effects; D005974:Glutamate-Ammonia Ligase / Q000235:genetics / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology; D051379:Mice; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013230:Stearoyl-CoA Desaturase / Q000235:genetics / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects; D014212:Tretinoin / Q000494:pharmacology*; D014404:Tubulin / Q000235:genetics / Q000378:metabolism
D002352:Carrier Proteins; D004268:DNA-Binding Proteins; C082667:Fabp5 protein, mouse; C086936:Fabp7 protein, mouse; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D007328:Insulin; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D011518:Proto-Oncogene Proteins; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D012333:RNA, Messenger; D014157:Transcription Factors; D014404:Tubulin; D014212:Tretinoin; D003907:Dexamethasone; D013230:Stearoyl-CoA Desaturase; D005974:Glutamate-Ammonia Ligase